News
The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback